The ACP guideline, published in Annals of Internal Medicine, includes three recommendations centered around monotherapy: ...

The American College of Physicians (ACP) has developed new recommendations to prevent episodic migraines in nonpregnant adults in outpatient settings.

The ACP issued new clinical guidance on preventing episodic migraines, classified as one to 14 headache days per month, in ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a ...

making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate response to at least two oral antidepressants.

The following is a summary of “Effectiveness and Safety of Ticagrelor Monotherapy After Short-Duration Dual Antiplatelet ...

Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind ...

The Clinical Guidelines Committee of the American College of Physicians (ACP) has released a new clinical guideline on the ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

The American College of Physicians (ACP) has developed new recommendations to prevent episodic migraines in nonpregnant ...